ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings is the market leader in orthopedic reconstructive implants with a large presence in the United States, Europe, and Japan. Despite the confusion surrounding their 1Q26 report, the company beat expectations on sales, margins, and EPS. However, crosscurrents such as account losses and a CFO departure dampened the overall outlook for the year. While the company's focus on orthopedic implants can be a blessing during good market conditions, challenges may arise in the form of pricing pressures and new market entrants. This, combined with significant exposure to international markets, warrants a hold rating for the stock and a price target of $92 based on a 10x P/E ratio.

Zimmer Biomet Holdings is currently in phase three of a growth-focused transformation, with healthy global elective procedure volumes, a new product innovation pipeline, and expanded capacity for M&A poised to support ongoing progress and gradually improve fundamentals in the years ahead. However, in 1Q, the company experienced a light performance in US knees due to sales force conversion and other issues, leading to a mixed quarter with a messy P&L. There may be upside potential to our negative outlook if the company sees a more rapid return to growth, uptake of key products, better-than-expected impacts from VBP, and lower-than-expected inflationary pressures.